Organon & Co. Statistics
Total Valuation
Organon & Co. has a market cap or net worth of $1.83 billion. The enterprise value is $9.99 billion.
| Market Cap | 1.83B |
| Enterprise Value | 9.99B |
Important Dates
The next estimated earnings date is Thursday, February 12, 2026, before market open.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | Nov 20, 2025 |
Share Statistics
Organon & Co. has 259.98 million shares outstanding. The number of shares has increased by 0.81% in one year.
| Current Share Class | 259.98M |
| Shares Outstanding | 259.98M |
| Shares Change (YoY) | +0.81% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 0.41% |
| Owned by Institutions (%) | 78.58% |
| Float | 258.67M |
Valuation Ratios
The trailing PE ratio is 3.69 and the forward PE ratio is 1.84. Organon & Co.'s PEG ratio is 1.45.
| PE Ratio | 3.69 |
| Forward PE | 1.84 |
| PS Ratio | 0.29 |
| Forward PS | 0.29 |
| PB Ratio | 2.06 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 2.36 |
| P/OCF Ratio | 1.93 |
| PEG Ratio | 1.45 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.91, with an EV/FCF ratio of 12.85.
| EV / Earnings | 19.94 |
| EV / Sales | 1.59 |
| EV / EBITDA | 5.91 |
| EV / EBIT | 7.41 |
| EV / FCF | 12.85 |
Financial Position
The company has a current ratio of 1.75, with a Debt / Equity ratio of 9.74.
| Current Ratio | 1.75 |
| Quick Ratio | 0.82 |
| Debt / Equity | 9.74 |
| Debt / EBITDA | 5.04 |
| Debt / FCF | 11.36 |
| Interest Coverage | 2.62 |
Financial Efficiency
Return on equity (ROE) is 71.62% and return on invested capital (ROIC) is 8.87%.
| Return on Equity (ROE) | 71.62% |
| Return on Assets (ROA) | 6.40% |
| Return on Invested Capital (ROIC) | 8.87% |
| Return on Capital Employed (ROCE) | 12.39% |
| Revenue Per Employee | $630,100 |
| Profits Per Employee | $50,100 |
| Employee Count | 10,000 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.95 |
Taxes
In the past 12 months, Organon & Co. has paid $201.00 million in taxes.
| Income Tax | 201.00M |
| Effective Tax Rate | 28.63% |
Stock Price Statistics
The stock price has decreased by -53.09% in the last 52 weeks. The beta is 0.54, so Organon & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -53.09% |
| 50-Day Moving Average | 7.38 |
| 200-Day Moving Average | 9.71 |
| Relative Strength Index (RSI) | 45.30 |
| Average Volume (20 Days) | 4,386,045 |
Short Selling Information
The latest short interest is 16.60 million, so 6.39% of the outstanding shares have been sold short.
| Short Interest | 16.60M |
| Short Previous Month | 15.59M |
| Short % of Shares Out | 6.39% |
| Short % of Float | 6.42% |
| Short Ratio (days to cover) | 3.44 |
Income Statement
In the last 12 months, Organon & Co. had revenue of $6.30 billion and earned $501.00 million in profits. Earnings per share was $1.91.
| Revenue | 6.30B |
| Gross Profit | 3.51B |
| Operating Income | 1.35B |
| Pretax Income | 702.00M |
| Net Income | 501.00M |
| EBITDA | 1.69B |
| EBIT | 1.35B |
| Earnings Per Share (EPS) | $1.91 |
Balance Sheet
The company has $672.00 million in cash and $8.83 billion in debt, giving a net cash position of -$8.16 billion or -$31.37 per share.
| Cash & Cash Equivalents | 672.00M |
| Total Debt | 8.83B |
| Net Cash | -8.16B |
| Net Cash Per Share | -$31.37 |
| Equity (Book Value) | 906.00M |
| Book Value Per Share | 3.48 |
| Working Capital | 2.02B |
Cash Flow
In the last 12 months, operating cash flow was $949.00 million and capital expenditures -$172.00 million, giving a free cash flow of $777.00 million.
| Operating Cash Flow | 949.00M |
| Capital Expenditures | -172.00M |
| Free Cash Flow | 777.00M |
| FCF Per Share | $2.99 |
Margins
Gross margin is 55.67%, with operating and profit margins of 21.38% and 7.95%.
| Gross Margin | 55.67% |
| Operating Margin | 21.38% |
| Pretax Margin | 11.14% |
| Profit Margin | 7.95% |
| EBITDA Margin | 26.81% |
| EBIT Margin | 21.38% |
| FCF Margin | 12.33% |
Dividends & Yields
This stock pays an annual dividend of $0.08, which amounts to a dividend yield of 1.14%.
| Dividend Per Share | $0.08 |
| Dividend Yield | 1.14% |
| Dividend Growth (YoY) | -69.64% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 17.78% |
| Buyback Yield | -0.81% |
| Shareholder Yield | 0.32% |
| Earnings Yield | 27.35% |
| FCF Yield | 42.42% |
Analyst Forecast
The average price target for Organon & Co. is $14.10, which is 100.00% higher than the current price. The consensus rating is "Hold".
| Price Target | $14.10 |
| Price Target Difference | 100.00% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 0.66% |
| EPS Growth Forecast (5Y) | 4.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Organon & Co. has an Altman Z-Score of 1.27 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.27 |
| Piotroski F-Score | 5 |